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Abstract Oncogenic PI3K/mTOR activation is frequently
observed in human cancers and activates cell motility via p27
phosphorylations at T157 and T198. Here we explored the
potential for a novel PI3K/mTOR inhibitor to inhibit tumor
invasion and metastasis. An MDA-MB-231 breast cancer
line variant, MDA-MB-231-1833, with high metastatic bone
tropism, was treated with a novel catalytic PI3K/mTOR
inhibitor, PF-04691502, at nM doses that did not impair
proliferation. Effects on tumor cell motility, invasion, p27
phosphorylation, localization, and bone metastatic out-
growth were assayed. MDA-MB-231-1833 showed
increased PI3K/mTOR activation, high levels of cytoplas-
mic p27pT157pT198 and increased cell motility and inva-
sion in vitro versus parental. PF-04691502 treatment, at a
dose that did not affect proliferation, reduced total and
cytoplasmic p27, decreased p27pT157pT198 and restored
cell motility and invasion to levels seen in MDA-MB-231.
p27 knockdown in MDA-MB-231-1833 phenocopied PI3K/
mTOR inhibition, whilst overexpression of the phosphomi-
metic mutant p27T157DT198D caused resistance to the
anti-invasive effects of PF-04691502. Pre-treatment of MDA-
MB-231-1833 with PF-04691502 significantly impaired
metastatic tumor formation in vivo, despite lack of antipro-
liferative effects in culture and little effect on primary
orthotopic tumor growth. A further link between cytoplas-
mic p27 and metastasis was provided by a study of primary
human breast cancers which showed cytoplasmic p27 is
associated with increased lymph nodal metastasis and
reduced survival. Novel PI3K/mTOR inhibitors may oppose
tumor metastasis independent of their growth inhibitory
effects, providing a rationale for clinical investigation of
PI3K/mTOR inhibitors in settings to prevent micrometas-
tasis. In primary human breast cancers, cytoplasmic p27 is
associated with worse outcomes and increased nodal
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metastasis, and may prove useful as a marker of both PI3K/
mTOR activation and PI3K/mTOR inhibitor efficacy.
Keywords p27  PI3K/mTOR  Cancer invasion 
Motility  Metastasis
Introduction
Mortality from breast and other cancers commonly results
from metastasis to distant organs including the liver and
lung; and bone metastasis can cause significant morbidity
[1]. Until recently, the lack of knowledge of molecular
mechanisms underlying metastasis has limited the devel-
opment of therapies that target tumor spread. Character-
ization of pathways that drive metastasis may yield
important new insights for better application of targeted
therapies.
The PI3K/mTOR pathway is activated in a majority of
human cancers through receptor tyrosine kinase activation
or amplification, PTEN loss, and activating mutations of
PIK3CA or other downstream effectors [2, 3]. The PI3K
pathway activates two mTOR complexes, mTOR complex
1 (mTORC1) and mTORC2, both of which coordinate cell
proliferation with nutrient availability via effects on many
biosynthetic processes [4]. In cancers, PI3K/mTOR pro-
motes cell survival and proliferation, and increasing data
also implicate this pathway in tumor invasion and metas-
tasis [2, 5]. ErbB2 overexpression has been shown to
promote lung metastasis from orthotopic breast cancer
xenografts via mTOR/Raptor-dependent p70S6K activation,
and activated p70S6K in primary human breast cancers was
correlated with increased metastasis [6]. Rictor [7] and
mTORC2-dependent AKT activation [8] have been impli-
cated in experimental lung metastasis. While increasing
data implicate PI3K/mTOR in tumor metastasis, mecha-
nisms underlying this remain poorly defined.
The CDK-inhibitor, p27, plays well-established roles in
cell cycle regulation, but has also been shown to have pro-
oncogenic functions in cancer independent of its effects on
the cell cycle [9]. As a nuclear CDK-inhibitor, p27
restrains normal cell growth, but in many cancers, consti-
tutive PI3K/mTOR activation drives kinases including
AKT [10–12], SGK [13], and RSK [14, 15] to phosphor-
ylate p27 at T157 and/or T198, which impairs nuclear p27
import [10] and leads to its accumulation in the cytoplasm.
Cytoplasmic p27 increases cell motility by RhoA inhibi-
tion, disrupting actin cytoskeletal stability [16]. p27-RhoA
binding is enhanced by p27 phosphorylation at T198 [14].
Evidence that pro-oncogenic effects of p27 were indepen-
dent of CDK inhibition came from mice expressing p27
defective for cyclin-CDK binding (p27CK-). p27CK-/CK-
knock-in mice show multi-organ hyperplasia (a p27 null
phenocopy), as well as cytoplasmic p27CK- localization
and spontaneous neoplasia [17]. Thus, oncogenic PI3K/
mTOR activation promotes cytoplasmic p27 accumulation,
increased cell migration, and may contribute to neoplastic
progression.
The frequent activation of PI3K/mTOR in human can-
cers has led to development of drugs that target these
pathways. Rapamycin and first-generation rapalogs are
allosteric inhibitors of mTORC1. With few exceptions,
most notably in renal cell carcinoma and mantle cell
lymphoma, these agents have showed limited efficacy as
single agents in clinical trials due to incomplete substrate-
specific mTORC1 inhibition and the activation of numer-
ous bypass pathways [3, 18]. This prompted development
of second-generation catalytic site inhibitors that target
PI3K, mTOR or both, many of which have shown promise
in preclinical studies and early clinical trials [3]. Dual
PI3K/mTOR inhibitors have potent antiproliferative and
pro-apoptotic effects in several human cancer xenograft
models [19–22]. While most studies have evaluated drug
efficacy against primary xenotumor growth, their ability to
inhibit tumor metastasis, the major cause of cancer patient
death, has not been systematically evaluated.
The present study provides in vivo evidence that PI3K/
mTOR activity is critical for the metastatic process in a
model of bone metastasis. The highly bone metastatic
variant of the MDA-MB-231 breast cancer model, 1833
[23], showed PI3K/mTOR activation, high levels of
p27pT157 and p27pT198, and p27-dependent motility/
invasion in vitro. The novel PI3K/mTOR catalytic site
inhibitor, PF-04691502, reduced p27 phosphorylation and
cytoplasmic accumulation, and impaired tumor cell inva-
sion. Moreover, this drug effectively impaired outgrowth of
bone metastases in vivo. p27CK-T157D/T198D transfec-
tion rendered cells resistant to inhibition of motility/inva-
sion by the PI3K/mTOR inhibitor, suggesting that the
activity of PF-04691502 is mediated in part by its action on
p27. These data implicate the PI3K/mTOR pathway as a
key mediator of tumor metastasis and reveal a novel
rationale for application of catalytic-site PI3K/mTOR
inhibitors in cancer therapy.
Results
Metastatic cells show PI3K/mTOR activation
and resistance to antiproliferative effects of PI3K/
mTOR inhibition at nM PF-04691502 doses
To investigate the role of PI3K/mTOR pathway activation in
tumor cell invasion and metastasis, we used a well-charac-
terized luciferase tagged MDA-MB-231 (hereafter 231)
breast cancer line variant, MDA-MB-231-1833 (hereafter
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1833), that consistently shows greater bone metastasis than
parental [23]. The 1833 cells demonstrated enhanced PI3K/
mTOR signaling relative to parental 231, with activation of
downstream kinases (Fig. 1a). PF-04691502 (hereafter
PF1502) is a potent, catalytic inhibitor of both PI3K and
mTOR kinases with antiproliferative effects at nanomolar
doses in vitro, and potent anti-tumor effects on multiple
xenografts in vivo [24]. Since drug-mediated loss of cell
survival or proliferation would abrogate metastasis, drug
levels were titrated to determine if effects on motility/inva-
sion could be distinguished from antiproliferative actions.
Treatment of both 231 and 1833 lines at 250 nM concen-
tration inhibited PI3K/mTOR effector kinase activities
(Fig. 1a) but neither 48 h (top) nor 7 day (bottom) continu-
ous drug exposures inhibited subsequent cell proliferation
over the following week (Fig. 1b) nor did this drug dose
inhibit cell cycle progression in either 231 or 1833 (Fig. 1c).
Indeed both 231 and 1833 were resistant to growth arrest by
PF1502 at drug doses that arrest other lines (see drug titration
in BT-20, 231 and 1833, Fig. 1d). At 250 nM, PF1502 did
not yield a sub-G1 fraction (Fig. 1d), nor did it reduce cell
viability or induce caspase 3 cleavage (Fig. 1e).
PI3K/mTOR inhibition impairs tumor cell motility
and invasion
Cellular adhesion as measured with the XCelligence Real-
Time Cell Analysis system (Fig. 2a and supplemental Fig
S1), migration by wound-healing assay (Fig. 2b), and
transwell matrigel invasion (Fig. 2c) were all decreased by
pretreatment of both 231 and 1833 cells with 250 nM
PF1502 for 48 h. The highly bone-metastatic 1833 cells
showed enhanced migration and markedly enhanced inva-
sion relative to parental 231 (Fig. 2b–c). Thus, PI3K/
mTOR inhibition, at a PF1502 dose that did not affect
proliferation or survival, abolished the excess motility and
invasion of 1833 over parental 231.
Increased cytoplasmic p27 in 1833 cells is reduced
by PF1502 treatment
While nuclear p27 plays an established role to inhibit G1-
phase cell cycle progression, recent work has implicated
cytoplasmic p27 in the promotion of cell motility [25].
PI3K/mTOR effector kinases, including AKT, RSK, and
SGK, phosphorylate C-terminal p27 residues T157 and
T198 causing its accumulation in the cytoplasm [25]. The
1833 cells had higher total p27 levels, p27 phosphorylation
at T157/T198 (Fig. 3a), and cytoplasmic p27 accumulation
compared to parental 231 (Fig. 3b). While most pro-
nounced in 1833, PF1502 (250 nM) decreased p27 T157/
T198 phosphorylation and reduced cytoplasmic p27
(Fig. 3a, b) in both lines. Notably, p27 knockdown in 1833
cells (Fig. 3c) reduced cell adhesion (Fig. 3d), and
impaired motility and matrigel invasion to a similar extent
as treatment with PF1502 (see Fig. 2b, c vs Fig. 3e, f).
Thus, loss of p27 in 1833 cells phenocopied in vitro effects
of PI3K/mTOR inhibition on cell adhesion, motility and
invasion. In the parental 231 line that lacked high cyto-
plasmic p27 (Fig. 3b), p27 knockdown did not significantly
affect motility and invasion.
p27CK-T157DT198D confers partial PF1502 resistance
If p27 critically mediates PI3K/mTOR effects on cell inva-
sion, a p27 phosphomimetic mutant should oppose the
PF1502-dependent reduction in motility and invasion. To
test this, a phosphomimetic p27T157DT198D mutant defec-
tive for cyclin-CDK interaction (p27CK-T157DT198D,
abbreviated p27CK-DD) was introduced into both 231 and
1833 cells (Fig. 4a). p27CK-DD increased 231 cell transwell
motility, and 231p27CK-DD was resistant to inhibition of
motility by PF1502 (Fig. 4b). Similarly, matrigel invasion
by 231p27CK-DD was greater than that of parental 231 cells
and was not significantly reduced by PF1502 (Fig. 4c).
Introduction of p27CK-DD into 1833 cells—that already
expressed high levels of cytoplasmic p27pT157pT198— did
not significantly increase matrigel invasion. Notably, while
PF1502 impaired invasion in 1833 (Fig. 2c), 1833p27
CK-DD cells were resistant to this effect (Fig. 4d). Thus,
cytoplasmic p27pT157pT198 plays a key role in mediating
PI3K/mTOR-dependent motility and invasion.
PI3K/mTOR inhibition reduces metastasis in vivo
Given the marked effect of PF1502 to inhibit cell motility
and invasion, we next assayed its effects on tumor metastasis
in vivo. To test if prolonged PI3K/mTOR inhibition in vitro
would affect the subsequent ability to establish bone
metastasis following intracardiac injection, cells were trea-
ted or not with PF1502 250 nM for 7 d followed by intra-
cardiac injection into nude mice (n = 10/group). Animals
received no further drug thereafter. These assays did not aim
to test anti-tumor effects per se but whether PI3K/mTOR
activity at the time of injection was required for manifesta-
tion of the metastatic phenotype. Viable tumor burden was
quantitated by in vivo imaging system (IVIS) of tumor bio-
luminescence and representative IVIS images, graphs of
photon flux over time and at the end of the experiment, and
bone metastasis histopathology are shown in Fig. 5a–d.
Untreated 1833 gave rise to more bone metastases than did
231 over 3 weeks, as expected [23]. While seven days of
250 nM PF1502 drug pre-treatment did not reduce sub-
sequent cell proliferation in vitro (Fig. 1), it significantly
reduced subsequent bone tumor formation by 1833 (Fig. 5a–
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Fig. 1 PF1502 inhibits PI3K/mTOR activity in MDA-MB-231 and
1833 without affecting proliferation or caspase activation. a Cells
were treated 48 h with 250 nM PF1502 or DMSO control prior to
Westerns of total and phospho-activated PI3K/mTOR effectors.
b Cells were pre-treated with 250 nM PF1502 for 48 h (top) or for
7 days (bottom) prior to seeding into cell culture without further drug
and subsequent population growth is plotted as cell number over time.
Mean cell number from triplicate repeats are plotted/time ± SEM
(comparative analysis of growth curves T test p = 0.10, p = 0.20).
c Flow cytometry of 231 and 1833 cells treated with 250 nM PF1502
or vehicle control for 48 h (Cell cycle distribution after 7 days of
therapy was also unchanged, not shown). Drug treatment did not yield
any sub-G1 fraction. d Flow cytometry for BT20, MDA-MB-231 and
1833 cells treated with increasing nM PF1502 doses for 48 h. Drug
treatment did not yield any sub-G1 fraction. e Caspase 3 cleavage
assay after 250 nM PF1502 for 48 h (left) or 7 days (right). Positive
control in far right lane shows MDA-MB-231 after 72 h of paclitaxel
100 nM
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c). Notably, an appreciable reduction in tumor biolumines-
cence was evident as early as 3 days post-injection (Sup-
plemental Fig S2), suggesting that PF1502 pre-treatment
may modulate early steps in this metastatic model (extrav-
asation and initial establishment of viable microcolonies).
PF1502 pre-treatment did not significantly alter bone
metastasis by parental 231 (Fig. 5a–c). The presence of
metastatic tumor in bone was verified histopathologically at
necropsy (Fig. 5d), but the decalcification required pre-
cluded tumor IHC assays for p27 and Ki67. Thus, at a dose
that fails to affect cell survival or proliferation in vitro,
PF1502 reduced the excess tumor cell motility, invasion, and
metastasis of highly PI3K/mTOR-activated 1833 to levels
seen with the parental 231 line.
It is noteworthy that while it significantly reduced bone
metastasis, a one-week PF1502 pre-treatment prior to
injection into each of two mammary fat pads did not sig-
nificantly decrease orthotopic growth of either 231 or 1833
tumors (n = 10 tumors each), consistent with its lack of
antiproliferative effect in cell culture (Fig. 5e). Of note,
lymph nodal metastasis from primary orthotopic tumors
appeared to be reduced by PI3K/mTOR inhibition of
injected cells: 4/5 animals injected with untreated cells
developed metastases while only 2/5 mice injected with
drug pre-treated cells yielded tumors metastatic to nodes
(see supplemental Fig S3, data not statistically significant).
Cytoplasmic p27 is linked to nodal metastasis
and reduced survival in breast cancer patients
To further address the link between cytoplasmic p27 and
metastasis, p27 localization was assessed by
Fig. 2 PI3K/mTOR inhibition attenuates tumor cell adhesion, motil-
ity, and invasion. Cells were pre-treated with PF1502 at 250 nM,
unless otherwise indicated, for 2 days prior to assays a Cell adhesion
in 1833 cells ± drug (mean ± SEM, T test for final time points vs
control, p \ 0.002) b Relative migration 6 h after wounding of a
confluent cell monolayer (graphed ± SEM, treated vs untreated T test
*p = 0.005). c Mean transwell matrigel invasion ± SEM (T test of
treated vs control *p = 0.02)
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immunohistochemistry in 100 primary breast cancers with
matched lymph nodal metastases (see Fig. 6a). Nuclear
p27 staining was greater in primary tumors than in nodal
metastases, with the mean % tumor nuclei positive for p27
stain 57.5 % in primary tumors and only 40 % in nodal
metastasis (p \ 0.0004). Cytoplasmic p27 staining showed
a trend toward increase between primary and nodal tumors.
The proportion of tumor cells showing cytoplasmic p27
staining in the primary cancers was positively associated
with the number of lymph nodes affected at diagnosis
(Spearman’s r = 0.22, one-sided p = 0.007), an early
indicator of distant metastatic potential (Fig. 6b). More-
over, cytoplasmic p27 was associated with reduced dis-
ease-free (two-sided p = 0.04, Log-rank test) and overall
survival (p = 0.05) for these node positive cancers, when
compared with cancers showing only nuclear p27 staining
at diagnosis (Fig. 6c, d). These in vivo data further support
the link between cytoplasmic p27 and metastatic tumor
progression in human breast cancer patients.
Discussion
PI3K/mTOR signaling promotes tumor progression by
activating cell proliferation, growth and survival [4] and has
been implicated in tumor metastasis. Here we provide evi-
dence that a novel catalytic PI3K/mTOR inhibitor may exert
anti-tumor effects by opposing metastasis. Inhibition of
effector kinases by the PI3K/mTOR inhibitor, PF1502,
decreased C-terminal phosphorylation of p27, reduced its
cytoplasmic localization, and attenuated tumor cell motility,
invasion and metastasis. That these effects occur at a drug
dose that failed to inhibit cell proliferation suggests that
processes governing tumor metastasis downstream of PI3K/
Fig. 3 PI3K/mTOR inhibition
reduces cytoplasmic p27 and
p27 knockdown phenocopies
PF1502 treatment. Cells were
treated 48 h with 250 nM
PF1502 or DMSO prior to
Westerns of: a Total p27,
p27pT157 and p27pT198 and
b p27 in cytosolic (C) and
nuclear (N) fractions. Cells were
infected with shRNA p27 (?) or
control (-) 5 days before the
following assays. c Relative p27
levels with and without shRNA-
mediated knockdown. d Cell
adhesion. e Mean relative
migration 24 h after wounding
of cell monolayer
(mean ± SEM T test *p = 0.01
for 1833 – vs ?shp27).
f Relative transwell matrigel
invasion over 24 h
(mean ± SEM T test *p \ 0.05
for 1833 – vs ?)
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mTOR may be independent of those driving proliferation.
Thus, PI3K/mTOR inhibition, in lines that appear resistant to
the compound’s antiproliferative action and indeed at a dose
that fails to prevent primary tumor growth, may have
potential to prevent or attenuate the establishment of
micrometastatic foci that initiate systemic tumor spread.
While there is evidence that both PI3K and mTOR path-
ways may contribute to metastasis, the mechanisms medi-
ating this are not well understood. In human breast cancers,
pAKT and p4EBP1 were greater in matched distant metas-
tases compared to primary tumors [26]. mTORC2-depen-
dent AKT activation increased ovarian cancer motility
in vitro and metastasis in vivo [8], and PI3K inhibition pre-
vented metastasis in a murine thyroid cancer model [27].
mTORC1 increased migration in gastric cancer cells [28],
mTORC2 drove migration and invasion in a glioma model
[29] and both Rictor and Raptor expression are required for
metastasis of a colorectal cancer xenograft [30]. While none
of these reports distinguished between effects on tumor
growth versus direct effects on metastasis, they raise the
possibility that PI3K/mTOR inhibition may not only impair
biosynthetic processes driving tumor growth, but also
modulate the metastatic process.
The CDK inhibitor p27 plays dual roles to regulate both
cell proliferation and motility. While p27 restrains normal
cell proliferation through cyclin-Cdk2 inhibition [9], it can
also modulate cell motility through mechanisms involving its
C-terminal domain [31, 32]. p27 can bind RhoA to inactivate
RhoA/ROCK and drive cell motility [16]. Motility effects of
p27 may exist in normal cells, since p27-dependent migration
is essential for normal cortical neuron development in vivo in
murine embryos [33, 34]. In cancers, oncogenic PI3K/mTOR
activation increases p27 phosphorylation at T157 and/or
T198 and promotes cytoplasmic p27 mislocalization [10–14].
Indeed, PI3K-mediated p27 phosphorylation at T198
enhances its binding to and inhibition of RhoA [14].
The balance between growth inhibitory and acquired
pro-motility/metastatic functions may determine effects of
Fig. 4 Expression of a
phosphomimetic, cell-cycle
inert p27 mutant conveys
resistance to PF1502. a Western
analysis shows GFP-p27CK-
T157DT198D (p27CK-DD)
expression in 231 and 1833
(control represents empty-
vector transfection).
b Migration in 231 ± PF1502
with or without p27CK-
T157DT198D, mean ± SEM
(T test of 231p27CK-DD [top]
and 231 [bottom] with or
without drug *p = 0.01,
p = 0.11; 231CK-DD versus.
231 control p \ 0.0001). c–d,
Matrigel invasion of 231
(C) and 1833 cells
(D) transduced with p27CK-
DD, with and without 48 h
PF1502 250 nM and
graphed ± SEM. (T-tests as
indicated: *p = 0.003,
p = 0.068 (left); *p = 0.0002,
p = 0.064 (right)). (c,d)
Representative
photomicrographs demonstrate
differential cell invasion with
and without p27CK-DD
expression in 231 and 1833
Breast Cancer Res Treat (2013) 138:369–381 375
123
p27 in different cancers. For example, p27 knockdown
increased proliferation and enhanced primary tumor forma-
tion in a Ras-driven mouse tumor model, but impaired tumor
invasion [35]. In many cancers, p27 protein levels are
reduced due to miRNA-mediated loss of synthesis or
accelerated proteolysis [9]. In contrast, tumors with activated
AKT exhibit abundant cytoplasmic p27 [9]. Cytoplasmic
p27 was implicated in local invasion in an AKT-driven
Fig. 5 PI3K/mTOR inhibition abrogates bone metastatic outgrowth
in vivo. 231 and 1833 were cultured ± 250 nM PF1502 for 7 days
prior to intracardiac injection. No further drug was given thereafter.
a Representative bioluminescence at 0, 7 and 21 days post-injection.
b Mean normalized photon flux (P/s, log scale) for 1833 (top) and 231
(bottom) ± SEM versus time (comparative analysis of growth curves,
*p values as indicated). c, Mean normalized photon flux (P/s) for
1833 and 231 at day 21 ± SEM. d, Representative bone metastasis
histopathology (tumor outlined in yellow). e Growth curves of
orthotopic tumors arising from 231 and 1833 cultured in vitro ±
250 nM PF1502 for 7 days prior to mammary fat pad injection
(p [ 0.50). Animals received no drug therapy. See also supplemental
Fig S2 showing nodal metastasis from orthotopic primary tumors
arising from drug-pretreated cells or controls
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human glioma xenograft [36] and overexpression of cyto-
plasmic p27CK- enhanced murine melanoma metastasis
[37].
Here we investigated further the link between PI3K/
mTOR activation, p27 and cancer metastasis. The well-
characterized highly bone-metastatic 1833 model showed
activation of PI3K and mTOR effector kinases and a p27-
dependent increase in cell motility and invasion in vitro.
The dual PI3K/mTOR inhibitor drug, PF1502, inhibited
PI3K as evidenced by decreased pPDK1, and effectively
impaired activation of both TORC1 and TORC2 substrates.
It also reduced C-terminal p27 phosphorylation, cytoplas-
mic p27 accumulation, and phenocopied effects of p27
knockdown to impair cell adhesion, motility, and invasion
in vitro. The p27CK-DD mutant, a T157/T198 phosp-
homimetic, increased motility and invasion of parental 231
cells. It also promoted resistance to in vitro effects of PI3K/
mTOR inhibition on invasion and motility in both 231 and
1833 cells. That the phosphomimetic p27 did not fully
reverse PF1502 effects on motility/invasion may reflect
that aspartate at T157/T198 fails to fully mimic phos-
phorylation, or that p27-independent mediators also con-
tribute to PI3K/mTOR driven tumor metastasis.
The present in vivo experimental approach was not
intended to mimic patient therapy, but rather to assay the
requirement for PI3K/mTOR pathway activity at the time
of injection for subsequent primary and metastatic tumor
outgrowth. Notably, prior PI3K/mTOR inhibition by
PF1502 that failed to restrain cell proliferation during or
after one week in culture in vitro, and did not reduce pri-
mary orthotopic tumor growth, significantly impaired the
subsequent outgrowth of bone metastatic tumors after
intracardiac injection in vivo. In addition, nodal metastasis
from orthotopic primary tumors also showed a trend toward
reduction with drug pre-treatment prior to injection. Thus,
drug effects to impair metastasis in this model appear to
occur despite the lack of an antiproliferative effect, and
may modulate tumor cell extravasation and establishment
of metastatic foci, as suggested by early IVIS data in the
first few days post-injection. Present data extend prior work
implicating PI3K and mTOR pathways in tumor growth
and metastasis [30, 38], and suggest that drug effects on
cell proliferation or growth may be separable from those
driving metastasis. Indeed, malignant progression of cells
resistant to antiproliferative effects of a novel PI3K/mTOR
kinase inhibitor may still be interdicted at the level of
metastasis—an effect that might be missed by traditional
phase 1 clinical trials focused on tumor size reduction.
A relationship between cytoplasmic p27 and metastasis is
supported by the novel observation that there is a positive
correlation between the % of primary breast cancer cells
Fig. 6 Cytoplasmic p27 correlates with lymph node invasion at
diagnosis and breast cancer outcome. a IHC demonstrating predom-
inantly nuclear (left) or strong nuclear ? cytoplasmic p27 staining
(right). b Primary tumor cytoplasmic p27 as it relates to number of
nodes positive at diagnosis. c Kaplan–Meier analysis of nuclear only
versus cytoplasmic positive tumors (N = 21 and N = 73, respec-
tively) and disease-free survival. d Kaplan–Meier analysis of nuclear
only versus cytoplasmic positive tumors and overall survival
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showing cytoplasmic p27 staining with the number of nodes
affected at diagnosis. While loss of nuclear p27 is strongly
associated with poor patient outcome [9], few studies have
addressed the prognostic import of cytoplasmic p27, which is
observed in up to 60 % of human cancers. Cytoplasmic p27
is correlated with poor outcome in colon and prostate cancers
and lymphoma [9]. p27 localization to cytoplasm in primary
breast cancers was associated with AKT activation[10–12].
The present study supports our earlier report associating
cytoplasmic p27 in primary breast cancer with a reduced
metastasis free interval [10], and provides the first associa-
tion with reduced patient survival.
PI3K and/or mTOR inhibitors have shown significant
therapeutic promise in a several cancers [3]. Dual PI3K/
mTOR catalytic-site inhibitors have begun to enter clinical
trials [3] and have shown improved anti-tumor effects over
allosteric mTORC1 inhibitors in pre-clinical models of breast
[19–21], pancreatic [22], and renal cell cancers [39], mela-
noma [40], glioma [21, 41], multiple myeloma [42], and acute
myeloid leukemia [43]. The present work suggests the anti-
proliferative effects of PI3K/mTOR inhibitor drugs may be
distinct from their anti-metastatic action. The latter may result
in part from their effects to abrogate cytoplasmic p27 accu-
mulation. This work has implications for the clinical appli-
cation of this new class of dual catalytic-site PI3K/mTOR
inhibitors: in addition to their effects to check primary tumor
growth, PI3K/mTOR inhibitors may also help prevent
establishment of metastasis by clinically occult tumor cells,
proving a rationale for trials investigating their potential to
prevent systemic metastases early in the disease course.
Furthermore, the presence of cytoplasmic p27 may identify
tumors with PI3K/mTOR activation and provide a potential
biomarker of PI3K/mTOR inhibitor therapeutic efficacy.
Methods
Cell culture and drug treatment
Luciferase tagged MDA-MB-231 and MDA-MB-1833 were
grown as in [44]. PF-04691502 was dissolved in DMSO,
stored at -80 C at 10 mM and used at 100-250 nM in
culture media. For prolonged treatment, drug was renewed
every 48 h in culture.
Antibodies and western blots
Westerns were as described [14]. Antibodies to p4EBP1,
4EBP1, pAKT, AKT, Caspase 3, pGSK3b, pPDK1, PDK1,
pRSK, pS6, S6, p27, GSK3b, RSK, pSGK, GFP and SGK
from Cell Signaling; RCC1 from Transduction labs and to
p27pT157 and p27pT198 from R&D.
Wound-healing and transwell migration assays
A linear scratch/wound was made on confluent cell mon-
olayers and wound healing assayed as described [14].
Relative migration was calculated by setting MDA-MB-
231 parental cell migration arbitrarily at 1 and adjusting all
other groups to that value.
Matrigel invasion assays
Transwell invasion assayed as in [14]. Relative invasion
was calculated setting invasion of control group to 1 and
comparing all other groups to that value.
Automated transwell and adhesion assays
Automated transwell and adhesion assays used the Real-
Time Cell Analysis system from Xcelligence. For adhesion
assays 20,000 cells were plated onto ‘‘E plates’’ from
Xcelligence and adhesion measured over 2 h. For transwell
migration assays, 20,000 cells were seeded onto a semi-
permeable membrane without matrigel in the upper
chamber in serum-free medium, with 10 % FBS added in
the bottom chamber. A two-sided t test was used to com-
pare the endpoint for each group in each experiment.
Lentiviral expression of p27 phosphomimetic mutants
Phosphomimetic p27 mutations converting T157 and T197
to aspartic acid were introduced into EGFP-p27CK- (S.
Dowdy, UCSD) by site-directed mutagenesis and trans-
fected into 231 and 1833, selected with G418 and pooled.
Lenteviral vectors bearing p27CK-T157DT198D phosp-
homimetic mutations were generated and transduced into
MDA-MB-231, and 1833.
Flow cytometry
Cell cycle distribution was assayed by Bromodeoxyuridine
(BrdU) pulse labelling and flow cytometry as described [14].
Intracellular localization of p27
Nuclear cytoplasmic fractionation was as described [10].
Nuclear RCC1 served as fractionation control. Cytoplasmic
proteins showed no leak into the nuclear fraction with this
methodology [10].
Lentiviral shRNA production and infection
Lentivirus vector encoding p27 shRNA (Open Biosystems)
was co-transfected with Delta VPR and CMV VSVG
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plasmids (Addgene) into asynchronous HEK-293T with
Lipofectamine Plus (Roche). Viral supernatants were col-
lected at 48 h. Cells were infected twice in the presence of
6 lg/ml protamine sulphate. At 3–5 days post infection,
high uniform GFP positivity was verified and p27 assayed
by blotting.
Animal studies
Animal work was approved by the Institutional Animal
Care and Use Committee. For bone metastasis assays, at
least ten animals in each arm were injected with 105 viable
cells in 0.1 ml PBS were injected into the left ventricle of
5 week old female Balb/c nude mice (Charles River) ± -
prior treatment in culture with 250 nM PF1502 or vehicle
control over the preceeding 7 days. Mice were injected
intraperitoneally with 1.5 mg of d-luciferin (15 mg ml-1 in
PBS) and imaged by Xenogen IVIS system on day 0 and
weekly thereafter as in [23]. Bioluminescence (BLI) plots
of photon flux were calculated for each mouse. Values
were normalized to that obtained immediately after xeno-
grafting (day 0) such that all mice had a starting BLI signal
of 100. Animals were weighed twice-weekly. Leg and
spinal tissues were recovered at necropsy at 3 weeks for
hemotoxylin and eosin (H & E) staining histopathology
unless morbidity required earlier euthanization. The
decalcification methods required for histopathologic anal-
ysis of bone metastasis precluded IHC for p27, Ki67 and
pS6 on xenograft tumors.
Similarly 231 and 1833 were treated ± 250 nM PF1502
for 7 d prior to orthotopic injection of 106 cells in 100 ll
matrigel into each of two mammary fat pads, with n = 5
animals (10 tumors) per group. Weekly IVIS followed
development of nodal metastasis from primary tumors.
Statistical analysis of growth/proliferation curves
The statistical differences between growth curves were cal-
culated using ‘compareGrowthCurves’ function of the stat-
mod software package at the following website (http://
bioinf.wehi.edu.au/software/compareCurves). This analysis
was applied for cellular proliferation assays, orthotopic
tumor growth curves, and IVIS metastatic tumor growth
curves.
Immunohistochemistry and analysis of human tumor
samples
One hundred primary human breast cancers and matched
nodal metastasis, and thirty primary node negative breast
cancers were obtained from the de-identified tumor bank
and database of UMSCCC Tissue Core Facility. p27 was
evaluated by immunohistochemistry as in [45]. The % cells
showing nuclear and/or cytoplasmic p27 staining was
scored independently by two pathologists (C. Milikowski
and T. Ince). Means (range) for the node positive group
were as follows: age 52 yrs (27–72), tumor size 4.3 cm
(1.2–18); # positive nodes 9 (1–53), follow-up 10 yrs
(0.8–27.5). 59 % were ER ? , 88 % grade 2 or 3, with
distant relapse in 62 %. p27 correlation with node posi-
tivity was scored using the Spearman analysis with node
number as a continuous variable. Kaplan–Meier curves
were generated for node-positive patients after excluding
primary tumors that showed no p27 staining (n = 3). Sta-
tistical significance was assessed by log rank test.
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